Medindia

X

Reportlinker Adds KOL insights and unmet needs in Ulcerative Colitis and Crohn's Disease

Wednesday, May 11, 2011 General News J E 4
Advertisement

NEW YORK, May 10, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0490908/KOL-insights-and-unmet-needs-in-Ulcerative-Colitis-and-Crohns-Disease.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Introductory offer: buy 2 Sociable Pharma reports get a third free. Introductory offer available until the end of May 2011.

Purchase Sociable Pharma's two reports on KOL insights and unmet needs in Ulcerative Colitis and Crohn's Disease and get Sociable Pharma view on future opportunities and scenarios free.

--Below are summaries of each report.

- Ulcerative Colitis: KOL insights on treatment practices and unmet needs

The use of biologics is still in its formative stages in the treatment of ulcerative colitis but adoption has already been significant and is set to expand considerably in the short- and medium-term. Sociable Pharma conducted in-depth primary research in the US and Europe with key opinion leaders to understand how these changes will impact therapy use in the future. We also gauged opinion during the European Crohn's & Colitis Organisation's (ECCO) Annual Congress on the impact that new clinical data for existing and pipeline products will have on treatment strategies employed by inflammatory bowel disease specialists.

HIGHLIGHTS

Identifies the latest treatment trends in Ulcerative Colitis, including the role of biologics in steroid-refractory patients and acute/severe settings

Based on key opinion leader interviews in the US and Europe, as well as the ECCO 2011 conference, supplemented with extensive secondary research on medical evidence and guidelines

Analyzes current treatment practices covering five major drug classes: aminosalicylates (5-ASAs), corticosteroids, immunomodulators, anti-TNF therapies, calcineurin inhibitors

Highlights opinion hotspots where treatment approaches differ between physicians and also between the US and Europe, such as the use of once daily oral dosing formulations for 5-ASAs

Assesses the impact of the 2011 SUCCESS trial

Identifies the most significant unmet needs, based on the treatment challenges facing physicians. Examples include adherence to 5-ASA regimens and managing long-term immunosuppression.

- Crohn's disease: KOL insights on treatment practices and unmet needs

Changes in therapeutic strategies for Crohn's disease are set to have a profound impact on its treatment landscape, exacerbating current and generating new treatment challenges for doctors, while presenting new and potentially lucrative opportunities for current and future market players. Sociable Pharma conducted in-depth primary research in the US and across Europe with six key opinion leaders to understand how these changes will impact therapy use in the future. We also gauged opinion during the European Crohn's & Colitis Organisation's (ECCO) Annual Congress on the impact that new clinical data for existing and pipeline products will have on treatment strategies employed by inflammatory bowel disease specialists.

HIGHLIGHTS

Identifies the latest treatment trends in Crohn's disease, including the growing importance of "top-down" treatment strategies for moderate-to-severe Crohn's disease

Based on key opinion leader interviews in the US and Europe, as well as the ECCO 2011 conference, supplemented with extensive secondary research on medical evidence and guidelines

Analyzes current treatment practices covering seven major drug classes: aminosalicylates (5-ASAs), corticosteroids, immunomodulators, anti-TNF therapies, antibiotics, probiotics and nutritional therapy

Highlights opinion hotspots where treatment approaches differ between physicians and also between the US and Europe, such as the emerging treatment objective of complete mucosal healing

Assesses the impact of the SONIC trial

- Crohn's disease: future treatment scenarios and opportunities

Changes in therapeutic strategies for Crohn's disease are set to have a profound impact on its treatment landscape, exacerbating current and generating new treatment challenges for doctors, while presenting new and potentially lucrative opportunities for current and future market players. Sociable Pharma conducted in-depth primary research in the US and across Europe with six key opinion leaders to understand how these changes will impact therapy use in the future. We also gauged opinion during the European Crohn's & Colitis Organisation's (ECCO) Annual Congress on the impact that new clinical data for existing and pipeline products will have on treatment strategies employed by inflammatory bowel disease specialists.

HIGHLIGHTS

Identifies the latest treatment trends in Crohn's disease, including the growing importance of "top-down" treatment strategies for moderate-to-severe Crohn's disease

Based on key opinion leader interviews in the US and Europe, as well as the ECCO 2011 conference, supplemented with extensive secondary research on medical evidence and guidelines

Identifies commercial opportunities in Crohn's disease treatment including:

1. Targeting patients na´ve to anti-TNF therapies with novel oral inhibitors

2. Combination therapies with helminth in mild-to-moderate disease

3. Improved localized release of corticosteroids to reduce systemic side effects

Assesses future scenarios for Crohn's disease therapies, including:

1. Migration of anti-TNF therapies to new treatment settings

2. Impact of tailored induction and maintenance regimens

3. Future use of antibiotics, probiotics and helminth in mild-to-moderate disease

To order this report:

Pathology Industry:

Pathology Business News

More áMarket Research Report

Check our áCompany Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Reportlinker Adds Medical Imaging Reports Bundle
S
Maine's Todd Grove Honored as Nation's Top Long-Te...